CN105664188A - 一种子宫输卵管腔道超声造影剂及其制备方法 - Google Patents
一种子宫输卵管腔道超声造影剂及其制备方法 Download PDFInfo
- Publication number
- CN105664188A CN105664188A CN201610102797.5A CN201610102797A CN105664188A CN 105664188 A CN105664188 A CN 105664188A CN 201610102797 A CN201610102797 A CN 201610102797A CN 105664188 A CN105664188 A CN 105664188A
- Authority
- CN
- China
- Prior art keywords
- component
- phospholipid
- contrast agent
- ligands specific
- polymeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 210000003101 oviduct Anatomy 0.000 title claims abstract description 14
- 210000004291 uterus Anatomy 0.000 title claims abstract description 8
- 239000002961 echo contrast media Substances 0.000 title abstract description 9
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 64
- 239000003446 ligand Substances 0.000 claims abstract description 43
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 23
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 239000003381 stabilizer Substances 0.000 claims abstract description 3
- 239000002872 contrast media Substances 0.000 claims description 53
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 26
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 20
- 229960000304 folic acid Drugs 0.000 claims description 20
- 235000019152 folic acid Nutrition 0.000 claims description 20
- 239000011724 folic acid Substances 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 13
- -1 Polyethylene Polymers 0.000 claims description 13
- 239000000787 lecithin Substances 0.000 claims description 13
- 229940067606 lecithin Drugs 0.000 claims description 13
- 235000010445 lecithin Nutrition 0.000 claims description 13
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 12
- 229910018503 SF6 Inorganic materials 0.000 claims description 12
- 229960000502 poloxamer Drugs 0.000 claims description 12
- 229920001983 poloxamer Polymers 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 238000002604 ultrasonography Methods 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 10
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 10
- 239000004005 microsphere Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229960004692 perflenapent Drugs 0.000 claims description 10
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 10
- 210000002706 plastid Anatomy 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 claims description 8
- 229960000909 sulfur hexafluoride Drugs 0.000 claims description 8
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 7
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 6
- PRPAGESBURMWTI-UHFFFAOYSA-N [C].[F] Chemical group [C].[F] PRPAGESBURMWTI-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 241001597008 Nomeidae Species 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 229940042880 natural phospholipid Drugs 0.000 claims description 4
- 238000010008 shearing Methods 0.000 claims description 4
- 239000008347 soybean phospholipid Substances 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 229940083466 soybean lecithin Drugs 0.000 claims description 3
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 claims description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical class CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 2
- 229960004065 perflutren Drugs 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 238000002601 radiography Methods 0.000 claims description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical group FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 2
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000725 suspension Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- LLXOATMJZSVSII-UHFFFAOYSA-N 2-[[1-(4-hydroxy-3-iodophenyl)-3-oxopyrrolidine-2-carbonyl]amino]ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=CC(C=2C(=CC=CC=2)C(F)(F)F)C=1C(=O)OCCNC(=O)C(C(CC1)=O)N1C1=CC=C(O)C(I)=C1 LLXOATMJZSVSII-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108010056384 CDPGYIGSR Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000010451 Folate receptor alpha Human genes 0.000 description 1
- 108050001931 Folate receptor alpha Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610102797.5A CN105664188B (zh) | 2016-02-24 | 2016-02-24 | 一种子宫输卵管腔道超声造影剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610102797.5A CN105664188B (zh) | 2016-02-24 | 2016-02-24 | 一种子宫输卵管腔道超声造影剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105664188A true CN105664188A (zh) | 2016-06-15 |
CN105664188B CN105664188B (zh) | 2018-06-08 |
Family
ID=56305384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610102797.5A Active CN105664188B (zh) | 2016-02-24 | 2016-02-24 | 一种子宫输卵管腔道超声造影剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105664188B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107184994A (zh) * | 2017-06-06 | 2017-09-22 | 山东省千佛山医院 | 一种肝癌超声诊断靶向试剂及其制备方法 |
CN107596393A (zh) * | 2017-11-01 | 2018-01-19 | 河北艾圣科技有限公司 | 负载治疗药物的超声造影剂及其制备方法 |
CN107952085A (zh) * | 2016-10-17 | 2018-04-24 | 北京凯莱天成医药科技有限公司 | 一种超声造影剂及其制备方法和用途 |
CN115487321A (zh) * | 2022-09-21 | 2022-12-20 | 青岛市肿瘤医院 | 一种用于宫颈癌超声造影的造影剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780284A (zh) * | 2009-01-15 | 2010-07-21 | 南方医科大学南方医院 | 磁性分子靶向超声造影剂微球及其制备方法 |
CN103099780A (zh) * | 2012-12-11 | 2013-05-15 | 中国科学院深圳先进技术研究院 | 制备含氢气微泡水溶液的方法,其产品及应用 |
CN104587497A (zh) * | 2014-12-26 | 2015-05-06 | 宁波市第一医院 | 叶酸受体靶向超声造影纳米微泡的制备方法 |
-
2016
- 2016-02-24 CN CN201610102797.5A patent/CN105664188B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780284A (zh) * | 2009-01-15 | 2010-07-21 | 南方医科大学南方医院 | 磁性分子靶向超声造影剂微球及其制备方法 |
CN103099780A (zh) * | 2012-12-11 | 2013-05-15 | 中国科学院深圳先进技术研究院 | 制备含氢气微泡水溶液的方法,其产品及应用 |
CN104587497A (zh) * | 2014-12-26 | 2015-05-06 | 宁波市第一医院 | 叶酸受体靶向超声造影纳米微泡的制备方法 |
Non-Patent Citations (1)
Title |
---|
潘弟仪等: "超声造影仪全氟丙烷脂质微球的制备与评价", 《中国药学杂志》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107952085A (zh) * | 2016-10-17 | 2018-04-24 | 北京凯莱天成医药科技有限公司 | 一种超声造影剂及其制备方法和用途 |
CN107184994A (zh) * | 2017-06-06 | 2017-09-22 | 山东省千佛山医院 | 一种肝癌超声诊断靶向试剂及其制备方法 |
CN107596393A (zh) * | 2017-11-01 | 2018-01-19 | 河北艾圣科技有限公司 | 负载治疗药物的超声造影剂及其制备方法 |
CN107596393B (zh) * | 2017-11-01 | 2020-06-09 | 河北艾圣科技有限公司 | 负载治疗药物的超声造影剂及其制备方法 |
CN115487321A (zh) * | 2022-09-21 | 2022-12-20 | 青岛市肿瘤医院 | 一种用于宫颈癌超声造影的造影剂及其制备方法 |
CN115487321B (zh) * | 2022-09-21 | 2023-10-31 | 青岛市肿瘤医院 | 一种用于宫颈癌超声造影的造影剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105664188B (zh) | 2018-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106267241B (zh) | 一种多功能多模态肿瘤特异性靶向相变型纳米微球光声造影剂及其应用 | |
AU627456B2 (en) | Ultrasonic contrast medium made up of small gas bubbles and fatty-acid-containing microparticles | |
CN100563718C (zh) | 用于反差成像的充气微囊组件 | |
FI81008B (fi) | Flytande blandning foer mottagning och stabilisering av gasbubblor foer anvaendning som kontrastmedel vid ultraljuddiagnostik. | |
CN101005858A (zh) | 用于反差成像的充气微泡组合物 | |
CN1897978B (zh) | 具有用于反差成像的活性组分的充气微囊组件 | |
CN105664188A (zh) | 一种子宫输卵管腔道超声造影剂及其制备方法 | |
BG103402A (bg) | Подобрения на, или свързани с контрастните средства | |
JP2014077006A (ja) | ナノスケールのコントラスト剤及びその使用方法 | |
CN101780284B (zh) | 磁性分子靶向超声造影剂微球及其制备方法 | |
US20210321985A1 (en) | Compositions and methods for targeted contrast agents for molecular imaging | |
CN107708742A (zh) | 诊断治疗用气泡制剂(tb)及其使用方法 | |
CN107206110A (zh) | 靶向的充气微囊制剂 | |
CN107213476A (zh) | 一种透明质酸修饰的硅包裹载药磷脂液态氟碳纳米球超声造影剂及其制备方法 | |
CN111632154A (zh) | 一种相转变纳米泡、其制备方法及用途 | |
Huang et al. | Smart responsive-calcium carbonate nanoparticles for dual-model cancer imaging and treatment | |
Wang et al. | Gadolinium-loaded solid lipid nanoparticles for colorectal tumor in MR colonography | |
Kumar et al. | FN3 linked nanobubbles as a targeted contrast agent for US imaging of cancer-associated human PD-L1 | |
JP2008526785A (ja) | 高密度焦点式超音波療法のための増強剤および同剤のスクリーニングの方法 | |
WO2024051474A1 (zh) | 脂质微泡冻干粉组合物及其制备方法 | |
CN105026030B (zh) | 充气微泡 | |
CN110639032B (zh) | 一种高频超声造影剂及其制备方法 | |
Peng et al. | Mesoporous Silica Nanoparticle-Based Imaging Agents for Hepatocellular Carcinoma Detection | |
CN109568610A (zh) | 一种基于Janus药物共轭体的诊疗微泡的制备方法和用途 | |
CN107233583A (zh) | 一种具有超长持续时间的超声造影剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Yuan Zhe Inventor after: Tao Xiumei Inventor after: Shi Jinghong Inventor after: Yang Ganying Inventor after: Wang Ruiqi Inventor after: Shang Lixia Inventor after: Leng Hongfei Inventor after: Xu Xiaoyu Inventor after: Liu Peiyan Inventor before: Yuan Zhe Inventor before: Yang Ganying |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180410 Address after: 050000 No. 2 building, International Park, run Jiang headquarters, No. 319 Changjiang Road, Shijiazhuang high tech Zone, Shijiazhuang, Hebei Applicant after: Hebei holy Technology Co., Ltd. Address before: Beijing City, Chaoyang District Qingnian Road 100123, 2, 8-4-301 Applicant before: Yuan Zhe Applicant before: Yang Ganying |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |